Prakash Raj taunts Yogi over his Tipu-Hanuman remarks in poll-bound Karnataka

Bengaluru, Jul 3: Over 35 acres of land in nine villages on the outskirts of Bengaluru have been earmarked for burial and cremation of bodies of COVID-19 victims after concerns were raised over the safety of funerals being held in burial grounds located in residential areas.

Deputy Commissioner of Bengaluru Urban District GN Shivamurthy issued an order setting apart about 35.5 acres in the villages under four Taluks of Bengaluru North, Bengaluru South, Anekal and Yelahanka.

The order directed the respective Tahsildars to register these chunks of land as reserved for burial grounds and not to use for any purpose.

According to the sources in the district administration, Karnataka Health Minister B Sriramulu and Revenue Minister R Ashoka had directed the officials to identify places on the city outskirts to dispose of the bodies of COVID-19 victims.

Mr Sriramulu had on Wednesday said COVID-19 victims will not be laid to rest in burial grounds in the city and separate places will be earmarked on the outskirts in the backdrop of safety concerns raised by public.

He had also warned against unscientific disposal of used Personal Protection Equipment kits worn by the families of the victim for the final rites, referring to reports about such instances.

In some places, people have also expressed concern over bodies of those who died of the coronavirus being buried in their neighbourhood.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

New Delhi, Jun 11: The Department of Pharmaceuticals has given its nod for lifting of ban on the export of hydroxychloroquine, Union Minister D V Sadananda Gowda said on Wednesday.

India had banned export of hydroxychloroquine on March 25, with some exceptions, amid views in some quarters that the drug could be used to fight COVID-19. On April 4, it completely banned the exports without any exception.

"Department of Pharmaceuticals has approved the lifting of ban on export of Hydroxychloroquine API as well as formulations. Manufacturers except SEZ/EOU Units have to supply 20 per cent production in the domestic market," the minister of chemicals and fertilisers said in a tweet.

The Directorate General of Foreign Trade (DGFT) has been asked to issue formal notification in this regard, he added.

In another tweet, Gowda said he held discussions with representatives of pharma companies along with some of his ministerial colleagues on the challenges being faced by the industry and on the roadmap to boost exports.

"Had detailed discussion with representatives of pharma companies & association, stakeholder Ministries along with Hon Ministers @piyushGoyal  ji, @HardeepSPuri  ji, & @MansukhMandviya  ji on entire gamut of challenges faced by the industry as well as strategies to boost pharma export," Gowda tweeted.

India exported hydroxychloroquine API (active pharmaceutical ingredient) worth USD 1.22 billion in April-January 2019-20.

During the same period, exports of formulations made from hydroxychloroquine was at USD 5.50 billion.